HOME >> MEDICINE >> NEWS
Drug-eluting stents adopted quickly, with early disparities

DURHAM, N.C. -- In the first comprehensive survey of its kind, Duke Clinical Research Institute researchers have documented that while the adoption of new drug-eluting stents has been rapid, their use has not been universally uniform among patients receiving them.

Furthermore, the researchers said, about one-third of the new stents were placed in patients with clinical characteristics for which such stent use has not yet been approved by the Food and Drug Administration (FDA). However, the researchers said that their finding of a high rate of "off-label" usage should be seen more as an impetus for further clinical trials rather than an immediate safety issue, since cardiologists have been placing traditional stents for more than 10 years and are comfortable with the procedure.

Stents are tiny mesh tubes that are inserted into the site of a blockage in a coronary artery that has been opened during balloon angioplasty. However, a principal complication of the procedure has been the high rate of treated arteries becoming blocked again, a process known as restenosis.

In an attempt to improve stents to keep treated arteries open, stent manufacturers coated them with a chemotherapeutic agent that limits the formation of scar tissue inside the artery. So far, clinical trials have shown that these new stents can reduce the restenosis rate to single digits from the 20 to 30 percent rate of the older stents. The first drug-eluting stent received FDA approval in April, 2003.

"Drug-eluting stents are truly breakthrough products in treating coronary artery disease, and in our analysis of the early trends of the their use, we found disparities in terms of age, race and socio-economic factors," said Duke cardiologist Sunil Rao, M.D., who presented the results of the Duke analysis Nov. 10, 2004, at the American Heart Association's annual scientific sessions in New Orleans.

"We also found that the rate of increased usage for off-label use was
'"/>

Contact: Richard Merritt
Merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
10-Nov-2004


Page: 1 2 3

Related medicine news :

1. Study finds drug eluting stents as effective as vascular brachytherapy in preventing restenosis
2. Study says rare allergic reactions to drug-eluting stents may raise risk for heart attack
3. Coronary stents do not improve long-term survival
4. Early reports of thrombosis after insertion of drug-eluting stents
5. Drug-coated stents effective in real world patients
6. Study highlights efficacy of sirolimus stents to prevent restenosis for PTS with CAD
7. Stanford computer model shows bypass surgery more cost-effective than stents
8. Research explores why some internationally adopted children excel while others struggle
9. Mandel School researchers receive $700,000 for study to promote well-being of adopted children
10. Sandia-developed foam likely would stop SARS virus quickly, Sandia/Kansas State team shows
11. New marker for early diagnosis of kidney failure identified

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of Enea, Scanlan & ... announce Westchester resident Lauren C. Enea has joined the firm as an associate attorney. ... her practice in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ( ... patients for colonoscopy at the HyGIeaCare® Center that is to be located adjacent ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration ...
(Date:3/24/2017)... Frederick, Maryland (PRWEB) , ... March 24, 2017 ... ... LLC, is the first Certified Medical Reiki™ Master in Frederick, MD. Judy says, ... and their caregivers during what is often a very difficult and challenging time.” ...
(Date:3/24/2017)... ... 24, 2017 , ... “End Time GPS”: a dauntless and enlightened study ... Time GPS” is the creation of published author, Wesley Gerboth, a World War II ... and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017  Zymo Research ... and Hamilton Robotics, Inc., who designs, manufactures ... ongoing collaboration that teams Zymo Research,s DNA ... and DNA extraction products with Hamilton,s high-throughput ... optimized methods for microbiomics and RNA isolation ...
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
(Date:3/24/2017)... 2017 A ReportsnReports.com report says, over the ... as the global sales of Adcetris and Kadcyla have been witnessing ... drug conjugates market is driven by large number of ADC drugs ... window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 Major Company Profiles, ...
Breaking Medicine Technology:
Cached News: